Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

The understanding of prostate cancer has significantly evolved in the past 15 years. Therefore, many people — including primary care providers — may not be aware of the current guidelines for prostate ...

Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...

A prostate-specific antigen (PSA) test is a blood test that measures a protein released in the blood by prostate cells. Both normal and cancerous prostate cells release the protein. Most of the time, ...

Higher persistent PSA levels post-surgery were linked to increased mortality risk, with 8-year prostate cancer–specific mortality reaching 13.86% for a prostate-specific antigen (PSA) ≥ 1 ng/mL. The ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

The NHS will prioritise menopause and prostate problems in its new digital hospital service, giving patients faster access to ...

Plans for a new NHS service being called an 'online hospital' have been unveiled - here's when patients are due to use it and ...